Medigene AG
MediGene AG english
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
POSITIVE PHASE 3 CLINICAL DATA FOR MEDIGENE’S POLYPHENON(TM)E
Munich / San Diego: October 15, 2001: the German-American biopharmaceutical
company MediGene (NMarkt: MDG), announced today positive data from the phase 3
clinical trial of Polyphenon(TM)E to treat genital warts. The multi-center
clinical trial involved 272 patients (50% males, 50% females) in 30 centers in
Europe in randomized, double-blinded and placebo-controlled trials of two
different formulations of Polyphenon(TM)E. The superior formulation reached a
clearance rate of as high as 61% for male patients and 57% for female patients.
Both formulations were well tolerated, with over 90% of patients reporting only
mild or moderate side effects. MediGene plans to insistently pursue further
development and regulatory approval of Polyphenon(TM)E. Currently there are few
effective treatment options for this disease estimated to affect 14 million
persons in Europe and North America.
– ends –
end of ad-hoc-announcement (c)DGAP 15.10.2001
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
This release contains forward-looking statements that involve risks and
uncertainties. The forward-looking statements contained herein represent the
judgement of MediGene as of the date of this release. These forward looking
statements are no guarantees for future performance, and the forward-looking
events discussed in this press release may not occur. MediGene disclaims any
intent or obligation to update any of these forward-looking statements.
——————————————————————————–
WKN: 502090; Index: NEMAX- 50
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
152235 Okt 01
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found